结核病研究(英文)最新文献_第3页

Critical Appraisal Focusing on Tuberculosis Risks among Displaced Persons: Do We Have a Smoking Gun? 关注流离失所者结核病风险的关键评估:我们有确凿的证据吗?

结核病研究(英文) Pub Date : 2022-01-01 DOI: 10.4236/jtr.2022.103007

C. Nwoke

引用次数: 0

Genetic Polymorphisms and Toxicities of First-Line Antituberculosis Drugs: Systematic Review of the Literature 一线抗结核药物的遗传多态性和毒性:文献系统综述

结核病研究(英文) Pub Date : 2022-01-01 DOI: 10.4236/jtr.2022.103010

Sekossounon Sanni, H. Sina, L. Baba-Moussa

{"title":"Genetic Polymorphisms and Toxicities of First-Line Antituberculosis Drugs: Systematic Review of the Literature","authors":"Sekossounon Sanni, H. Sina, L. Baba-Moussa","doi":"10.4236/jtr.2022.103010","DOIUrl":"https://doi.org/10.4236/jtr.2022.103010","url":null,"abstract":"Introduction: Polymorphisms are the main genetic factors associated with toxicities of antituberculosis drugs. This literature review summarizes the polymorphisms of the genes that code for the enzymes of the metabolism of antituberculosis drugs and their transmembrane transporters. Some mechanisms of drug-associated toxicities and strategies for their management have also been described in this review. Methods: The bibliographic searches were exclusively carried out in PubMed, over a period of ten years (2010-2020). The search terms were the words “toxicity + antituberculosis drug + one or two word(s) among the following: polymorphism, genetics, mutation, SNP, HLA or haplotype”. Publications in English or French, relating to the various toxicities associated with first-line anti-tuberculosis drugs (Rifampicin, Isoniazid, Ethambutol and Pyrazinamide) administered to patients with pulmonary tuberculosis, extrapulmonary tuberculosis or co-infected with TB/HIV were included in this review. Duplicates, in vitro, in silico or drug-induced toxicity studies other than antituberculosis drugs and genetic mutations of Mycobacteria strains were not included. Results: The studies selected and included were case reports, cohort studies, original research, systematic reviews and meta-analyses on human subjects of polymorphisms (TXNRD1, SOD2, TYMP) have been suspected but their mechanisms are not yet well understood.","PeriodicalId":70603,"journal":{"name":"结核病研究(英文)","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70459404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Strategic Engagement of Private Facilities to Increase Public-Private Mix (PPM) Contribution to Nigeria Tuberculosis Case Notification 私营机构的战略参与，以增加公私混合对尼日利亚结核病病例通报的贡献

结核病研究(英文) Pub Date : 2022-01-01 DOI: 10.4236/jtr.2022.103008

O. Chijioke-Akaniro, E. Ubochioma, A. Omoniyi, Oluwafunmilayo Omosebi, Olawumi Olarewaju, Mary Etolue, S. Asuke, E. Aniwada, Anyaele Uwaezuoke Ndubuisi, V. Ombeka, Aderonke Agbaje, A. Lawanson, C. Anyaike

{"title":"Strategic Engagement of Private Facilities to Increase Public-Private Mix (PPM) Contribution to Nigeria Tuberculosis Case Notification","authors":"O. Chijioke-Akaniro, E. Ubochioma, A. Omoniyi, Oluwafunmilayo Omosebi, Olawumi Olarewaju, Mary Etolue, S. Asuke, E. Aniwada, Anyaele Uwaezuoke Ndubuisi, V. Ombeka, Aderonke Agbaje, A. Lawanson, C. Anyaike","doi":"10.4236/jtr.2022.103008","DOIUrl":"https://doi.org/10.4236/jtr.2022.103008","url":null,"abstract":"Introduction: Finding the missing Tuberculosis (TB) cases remains the single most important priority for TB control in Nigeria. Between 66% - 92% of all cases of respiratory diseases including those with symptoms suggestive of TB are first seen byprivate health providers. Dependable, quality surveillance systems and notification are key roles in health services delivery, particularly as it is related to TB control. However, poor notification has been a challenge. This study was to assess the contribution of the public private mix (PPM) to Nigeria Tuberculosis national case notification. Methods: It was a national cross-sectional study. Data were extracted from the National database and reviewed. Private facilities were engaged in 2017 and assessed over 2018-2020. Interventions included: enrolling private practitioners (Private-For-Profit, Faith Based Organization, Private Medicine Vendors and Community Pharmacists), engaging a private standalone Laboratory for Gene Xpert testing within the network of private facilities, use of Mobile App for easy screening and reporting, instituting in 2019 and 38,865 in 2020. There were 18.0% increase in 2018, 36.6% in 2019 and 125.3% increase in 2020 (p < 0.001). Conclusion: Effective engagement of the private sector in TB control efforts in Nigeria using a variety of approaches resulting in improved TB notification is possible. The National TB Programme should engage all private practitioners such that each practitioner will practice at least one TB service model.","PeriodicalId":70603,"journal":{"name":"结核病研究(英文)","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70459339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Identifying Factors that Affect the Probability of Being Cured from MDR-TB Disease, KwaZulu-Natal, South Africa: A Competing Risks Analysis 确定影响耐多药结核病治愈可能性的因素，夸祖鲁-纳塔尔省，南非:竞争风险分析

结核病研究(英文) Pub Date : 2022-01-01 DOI: 10.4236/jtr.2022.101001

S. Mbona, H. Mwambi, R. Chifurira

{"title":"Identifying Factors that Affect the Probability of Being Cured from MDR-TB Disease, KwaZulu-Natal, South Africa: A Competing Risks Analysis","authors":"S. Mbona, H. Mwambi, R. Chifurira","doi":"10.4236/jtr.2022.101001","DOIUrl":"https://doi.org/10.4236/jtr.2022.101001","url":null,"abstract":"Setting: Four decentralised sites are located in rural areas and one centralised hospital in KwaZulu-Natal province, South Africa. Objective: To analyse risk factors associated with multidrug-resistant tuberculosis (MDR-TB) using competing risks analysis. Understanding factors associated with MDR-TB and obtaining valid parameter estimates could help in designing control and in-tervention strategies to lower TB mortality. Method: A prospective study was performed using a competing risk analysis in patients receiving treatment for MDR-TB. The study focused on 1542 patients (aged 18 years and older) who were diagnosed of MDR-TB between July 2008 and June 2010. Time to cure MDR-TB was used as the dependent variable and time to death was the competing risk event. Results: The Fine-Gray regression model indicated that baseline weight was highly significant with sub-distribution hazard ration (SHR) = 1.02, 95% CI: 1.01 - 1.02. This means that weight gain in a month increased chances of curing MDR-TB by 2%. Results show that lower chances to cure MDR-TB were among patients between 41 to 50 years compared to those patients who were between 18 to 30 years old (SHR = 0.80, 95% CI: 0.61 - 1.06). The chances of curing MDR-TB reduce mortality of patients due to TB disease, hence positive treatment outcomes leading to the goal of reducing or end TB deaths. Urgent action is required to improve the coverage and quality of diagnosis, treatment and care for people with drug-resistant TB.","PeriodicalId":70603,"journal":{"name":"结核病研究(英文)","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70459144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Candidate Vaccines against Tuberculosis and the Future of Novel TB Vaccine Research 结核病候选疫苗和新型结核病疫苗研究的未来

结核病研究(英文) Pub Date : 2022-01-01 DOI: 10.4236/jtr.2022.104018

Ochran Chetty, Cohen Chetty

引用次数: 0

Risk Factors and Complications in 947 Tuberculosis Patients Hospitalized in the Pulmonology Department of Fann Chnu from 2017 to 2019 2017 - 2019年福建省肺科住院947例肺结核患者危险因素及并发症分析

结核病研究(英文) Pub Date : 2022-01-01 DOI: 10.4236/jtr.2022.104013

M. F. Cisse, Emmanuella Mahugnon Tognimassou, S. Niang, Fatimata Binetou Rassoule Mbaye, K. Thiam, Y. Kane, N. Toure

引用次数: 0

Patient and Health System Factors Associated with First Line Tuberculosis Treatment Adherence, 2009-2014 2009-2014年与一线结核病治疗依从性相关的患者和卫生系统因素

结核病研究(英文) Pub Date : 2022-01-01 DOI: 10.4236/jtr.2022.104017

Gifty Adu, B. Harris, A. Beke